Skip to main content

Table 1 Characteristics of patients with middle to lower third rectal adenocarcinoma, receiving neoadjuvant concurrent chemoradiotherapy followed by trans-anal total mesorectal excision assisted by single port laparoscopic surgery

From: Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

 

n (%)

Sex

 Male

13 (56.52)

 Female

10 (43.48)

Age, median (range)

63 (31-80)

BMI (kg/m2), median (range)

23.7 (18-32)

ASA

 

 ASA score 1

1 (4.35)

 ASA score 2

19 (82.61)

 ASA score 3

3 (13.04)

Distance to anal verge (mm), median (range)

54 (20-80)

Tumor size (mm), median (range)

20 (6-85)

AJCC clinical stages

 Stage II

8 (34.78)

 Stage III

15 (65.22)

Clinical T stage

 cT2

2 (8.70)

 cT3

21 (91.30)

Clinical N stage

 cN0

8 (34.78)

 cN1

11 (47.83)

 cN2

4 (17.39)

Neoadjuvant CCRT

23 (100.00)

  1. ASA American Society of Anesthesiologists, BMI body mass index, CCRT concurrent chemoradiotherapy, AJCC the American Joint Committee on Cancer